Literature DB >> 19646299

Treatment results for ethmoid sinus carcinoma.

J R Gras-Cabrerizo1, J R Montserrat-Gili, X León-Vintró, H Massegur-Solench, J M de Vega, D Virós-Porcuna.   

Abstract

OBJECTIVE: The aim of this study was to describe the results of treatment in patients with ethmoid sinus carcinoma. MATERIALS AND
METHOD: We performed a retrospective study of 34 patients with carcinoma of the ethmoid sinus, and collected the following data: age, sex, employment, tobacco and alcohol consumption, tumour-node-metastasis stage, treatment, and survival.
RESULTS: The mean patient age was 64 years. Seventy-six per cent of patients were men and 24 per cent women. Squamous cell carcinoma was the most frequent histological tumour type (44 per cent). Eleven patients were classified as T(2), six as T(3), six as T(4a) and 11 as T(4b). Two patients (6 per cent) had nodal metastasis at the time of diagnosis. The anterior skull base was involved in 17 patients (50 per cent) and the anterior orbital contents were affected in seven patients (21 per cent). The five-year actuarial observed survival rate for all patients was 44 per cent.
CONCLUSIONS: Combined treatment with surgery and post-operative radiotherapy permitted good local control in patients with ethmoid sinus carcinoma. We do not recommend prophylactic neck treatment for ethmoid sinus carcinoma.

Entities:  

Mesh:

Year:  2009        PMID: 19646299     DOI: 10.1017/S0022215109990752

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  [Sinonasal tract malignancies : a 14-year single institution experience].

Authors:  A Schröck; F Göke; T van Bremen; R Kirsten; M Jakob; T Ehrenberg; M Kühnemund; A Gerstner; K W G Eichhorn
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

2.  Survival Outcome of Squamous Cell Carcinoma Arising from Sinonasal Inverted Papilloma.

Authors:  Qing-Zhuang Liang; De-Zhi Li; Xiao-Lei Wang; Hui Huang; Zhen-Gang Xu; Yue-Huang Wu
Journal:  Chin Med J (Engl)       Date:  2015-09-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.